文献速递神经MR

动态对比增强MRI或可预测复发高级别胶质瘤贝伐珠单抗治疗反应与预后

Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging.
PubMed 文献 · Neuroradiology · 2021-03-23

反应者(n=16)PFS和OS显著长于非反应者(n=37)(P<0.001);多因素分析示较低平均Kep是良好反应的唯一独立预测因素(OR=0.01,P=0.008),较高平均Kep与更短PFS(HR=7.90,P=0.006)和OS(HR=9.71,P=0.020)相关。

要点

  • 基线DCE-MRI的平均Kep可能用于预测贝伐珠单抗治疗反应。
  • 较低平均Kep与良好治疗反应独立相关(OR=0.01)。
  • 较高平均Kep与更短PFS和OS相关(HR分别为7.90和9.71)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: We aimed to evaluate the utility of diffusion tensor imaging (DTI), dynamic contrast-enhanced (DCE), and dynamic susceptibility contrast (DSC) imaging for stratifying bevacizumab treatment outcomes in patients with recurrent high-grade glioma.

METHODS: Fifty-three patients with recurrent high-grade glioma who underwent baseline magnetic resonance imaging including DTI, DCE, and DSC before bevacizumab treatment were included. The mean apparent diffusion coefficient, fractional anisotropy, normalized cerebral blood volume, normalized cerebral blood flow, volume transfer constant, rate transfer coefficient (Kep), extravascular extracellular volume fraction, and plasma volume fraction were assessed. Predictors of response status, progression-free survival (PFS), and overall survival (OS) were determined using logistic regression and Cox proportional hazard modeling.

RESULTS: Responders (n = 16) showed significantly longer PFS and OS (P < 0.001) compared with nonresponders (n = 37). Multivariable analysis revealed that lower mean Kep (odds ratio = 0.01, P = 0.008) was the only independent predictor of favorable response after adjustment for age, isocitrate dehydrogenase (IDH) mutation status, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. Multivariable Cox proportional hazard modeling showed that a higher mean Kep was the only variable associated with shorter PFS (hazard ratio [HR] = 7.90, P = 0.006) and OS (HR = 9.71, P = 0.020) after adjustment for age, IDH mutation status, and MGMT promoter methylation status.

CONCLUSION: Baseline mean Kep may be a useful biomarker for predicting response and stratifying patient outcomes following bevacizumab treatment in patients with recurrent high-grade glioma.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Park YW, Ahn SS, Moon JH, et al. Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging. Neuroradiology. 2021. PMID: 33755766. doi:10.1007/s00234-021-02693-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。